The unstoppable rise of super-resistant strains of bacteria is a serious worldwide problem, resulting in 700000 deaths every year according to the Review on Antimicrobial Resistance commissioned by the UK Prime Minister. Unfortunately, the acquisition of bacterial resistance seems to be outpacing our ability to develop new antibiotics, and we are now facing the real possibility of a reversion to the pre-antibiotic era.

Different countermeasures can be taken to slow down the process and increase the likelihood that researchers worldwide will develop new, effective antimicrobial therapies in time. Some of these actions would be relatively easy to adopt and could play a major role against the threat of antibiotic resistance. Stopping over-prescription and inappropriate use of antibiotics represents the first example: in Europe, 30-50% of prescribed antimicrobials are unnecessary, according to the European Centre for Disease Prevention and Control (ECDC). In some cases, the issue could be even easier to address: south Asia is currently experiencing a health disaster due to the spread of extremely drug-resistant typhoid. According to Edward Ryan of the Harvard T H Chan School of Public Health (Boston, USA), the 'real prevention' in this situation simply relies on improved water, sanitation and hygiene (WASH). In addition to these, black market distribution as well as extensive use of antibiotics in the farming industry represent two different threats that massively contribute to the development of multidrug resistance (MDR). Stronger efforts should be taken in order to stop the first and regulate the latter.

Although some of these measures appear to be rather simple to adopt, a real change is yet to come, as exemplified by the recent findings of Benjamin Howden of the University of Melbourne (Australia). In a paper published in *Nature Microbiology* on September 3, 2018, he warned about the global spread of three pan-resistant lineages of *Staphylococcus epidermis* that dominate hospital environments worldwide and emerged independently. Howden suggested that co-prescription of vancomycin and rifampicin is promoting the generation of resistance to both agents and called for a review of the present clinical guidelines as well as a better surveillance routine.

A good strategy for clinicians would be the use of current knowledge to find the best combination therapy approaches to treat resistant strains with already existing antibiotics. In some cases, such as for *Clostridium difficile* infection, the options we have can still be effective if used properly, as suggested by Herbert L DuPont from University of Texas (Houston, USA) in his systematic review published on July 16, 2018 in *The Lancet Infectious Diseases*.

The need for immediate action is clear, and *EBioMedicine* highlighted the adoption of the Global Action Plan on Antimicrobial Resistance (AMR) by World Health Assembly in 2015. Steps have been taken since then, with the development of the World Health Organization (WHO)'s Global Antimicrobial Resistance Surveillance System (GLASS), which included information from 40 countries in its first report in 2017. The 2018 World Health Assembly goals include implementation of national AMR surveillance systems and supporting low-income countries to enrol in GLASS.

The use of antimicrobial susceptibility testing (AST) technologies can help accelerate the initiation of targeted antimicrobial therapy, but there are still several barriers preventing the timely development and implementation of novel and rapid AST platforms in health care settings. This has been well described by Alex van Belkum from the Data Analytics Unit of BioMérieux (La Balme Les Grottes, France) in the Consensus Statement published in *Nature Reviews Microbiology* on October 17, 2018, following up the discussions of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) Working Group on Rapid Diagnostic Testing.

Although rapid tests already exist, the availability of and the access to those tests do not always result in their increased use, and van Belkum reported that the decision to use AST largely varies across providers. There is still much room for improvement, and better communication and collaboration between the public, academia, patient groups, policy makers and industry have the potential to lead to better strategies both for surveillance and for the development of new antimicrobials. In this context, the College of American Pathologists (CAP) calls for the generation of 'institutional antibiograms' aimed at assessing local MDR trends. In an era of personalized medicine, machine learning algorithms can integrate those traditional antibiograms into 'smart antibiograms', where historical trends can be used for predicting the best therapy for new patients.

In synchrony with global health organizations, researchers are also mobilizing to find new approaches to fight resistance. An inspiring example has been recently reported in *Nature* on September 12, 2018: Peter Smith and colleagues at Genentech (San Francisco, USA) developed a new molecule, G0775, by chemical optimization of the natural compound aryolmicyn. G0775 uses a novel mechanism of action to pass the MDR Gram-negative bacteria outer membrane and exerts a potent, broad-spectrum antimicrobial activity, which has been proven *in vitro* and in several preclinical *in vivo* models. This is promising news but, of course, there is still a long path for G0775 to move towards clinical utilisation. A stunning result in this direction has been reported in *The Lancet Infectious Diseases* on October 25, 2018. Simon Portsmouth and his colleagues at Shionogi Inc (Florham Park, USA) tested cefiderocol (S-649266), a new antibiotic for carbapenem-resistant Gram-negative bacteria, in a phase 2 clinical trial (NCT02321800). The drug uses a simple trick to circumvent the bacterial defences. The authors exploited the iron-poor environment typical of an acute infection, and the subsequent increase in bacterial iron intake to develop a 'Trojan horse' strategy for cefiderocol entry into bacterial cells. The antibiotic binds to iron, and this tricks bacteria, which transport it inside their membrane. The antibiotic was proven to be effective, safe and tolerable and the authors are now planning to submit a New Drug Application to the US Food and Drug Administration. This represents a remarkable advance: it is indeed more than fifty years since new classes of antibiotics against Gram-negative bacteria have been approved.

Although MDR is undoubtedly a plague of our times, the joint activity of global health systems, implementation of technology platforms, and integrating research efforts are hoping to generate an advantage in this race between antibiotics development and bacterial resistance. This huge mobilisation will hopefully ensure that we stay a step ahead of the bacterial threat, but, to be really safe, this momentum has to induce a global awareness and will to change. The responsibility for this to be long-lasting belongs not only to those organizations, but to the whole population including antibiotics end-users - that is all of us.
